Stevanović, Stefan

Actively personalized vaccination trial for newly diagnosed glioblastoma

Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature

Glioma Diagnosis and TreatmentImmunotherapy and Immune Responses

Cited by 938

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

Nelde, A., Bilich, T., Heitmann, J. S., Maringer, Y., Salih, H. R., Roerden, M., Lübke, M., Bauer, J., Rieth, J., Wacker, M., et al. (2021) · Nature Immunology

vaccines and immunoinformatics approachesSARS-CoV-2 and COVID-19 Research

Cited by 582

HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy

Marcu, A., Bichmann, L., Kuchenbecker, L., Kowalewski, D. J., Freudenmann, L. K., Backert, L., Mühlenbruch, L., Szolek, A., Lübke, M., Wagner, P., et al. (2021) · Journal for ImmunoTherapy of Cancer

vaccines and immunoinformatics approachesImmunotherapy and Immune Responses

Cited by 250

Promiscuous survivin peptide induces robust CD4+ T‐cell responses in the majority of vaccinated cancer patients

Widenmeyer, M., Griesemann, H., Stevanović, S., Feyerabend, S., Klein, R., Attig, S., Hennenlotter, J., Wernet, D., Kuprash, D. V., Sazykin, A. Y., et al. (2012) · International Journal of Cancer

Immunotherapy and Immune Responsesvaccines and immunoinformatics approaches

Cited by 70

Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA‐B44 supertype

Hillen, N., Mester, G., Lemmel, C., Weinzierl, A. O., Müller, M., Wernet, D., Hennenlotter, J., Stenzl, A., Rammensee, H., & Stevanović, S. (2008) · European Journal of Immunology

vaccines and immunoinformatics approachesImmunotherapy and Immune Responses

Cited by 43